NAFLD is the accumulation of fat in liver cells not caused by alcohol, affecting up to 25% of adults globally. It ranges from simple steatosis to NASH (non-alcoholic steatohepatitis), which can progress to cirrhosis; lifestyle modification is the primary treatment.
Gastrointestinal and hepatic conditions generate complications through mucosal barrier dysfunction, impaired nutrient absorption, portal hypertension, altered motility, and systemic effects of hepatic failure. Liver cirrhosis exemplifies the multi-system complication burden: portal hypertension causes variceal bleeding, ascites, and hepatorenal syndrome; liver synthetic failure impairs coagulation; portosystemic encephalopathy affects consciousness. Inflammatory bowel disease carries complications from bowel wall inflammation, malabsorption, extraintestinal manifestations, and immunosuppressive therapy.
Immediate clinical action required
The following signs may indicate a new or worsening complication requiring prompt clinical evaluation:
Treatment & Management
Evidence-based treatment pathway, medications, and escalation criteria
Prognosis & Outlook
Long-term clinical outlook, improving and worsening outcome factors
Differential Diagnosis
Conditions that mimic Non-Alcoholic Fatty Liver Disease (NAFLD) — distinguishing features & tests
Non-Alcoholic Fatty Liver Disease (NAFLD) Overview
Symptoms, causes, and general condition overview
Describe your symptoms and get a structured clinical assessment — possible causes, red flags, and recommended next steps.
Start Free AI Analysis →Content on this page is informed by evidence-based clinical sources including: